VEGFR2/KDR Antagonist - 1 mg
- Cat.Number : AS-60628
- Manufacturer Ref. :
-
Availability :
In stock
This peptide is a specific VEGFR2/KDR heptapeptide antagonist, it binds VEGFR2 (KDR/flk), completely inhibiting VEGF binding to KDR and preventing VEGF-induced angiogenesis in-vivo. It specifically inhibits human endothelial cell proliferation in-vitro and totally abolishes VEGF-induced angiogenesis in-vivo.
Specifications
| Chemistry | |
| Sequence one letter code |
|
|---|---|
| Sequence three letter code |
|
| Molecular Formula |
|
| Molecular Mass/ Weight |
|
| Modification | |
| Conjugation |
|
| Quantity & Purity | |
| Purity |
|
| Storage & stability | |
| Form |
|
| Storage Conditions |
|
| Activity | |
| Biomarker Target | |
| Research Area | |
| Sub-category Research Area | |
| Usage |
|
| Source | |
| Source / Species |
|
| Codes | |
| Code Nacres |
|
You may also be interested in the following product(s)
SensoLyte® Rh110 Matriptase Activity Assay Kit Fluorimetric - 1 kit
Citations
Hyperoxia causes regression of vitreous neovascularization by downregulating VEGF/VEGFR2 pathway.
Invest Ophthalmol Vis Sci . 2013 Feb 18 ; 54(2) 918 | DOI : 10.1167/iovs.12-11291.
- H. Liu
- et al
Selective photodynamic therapy by targeted Verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2
Arch Ophthalmol. . 2004 Jul 01 ; 122(7) 1002 | DOI : 10.1001/archopht.122.7.1002
- RZ. Renno
- et al